Astaxanthin: Past, Present, and Future
Marine Drugs · 28.09.2023 · 21 (10) · 514
DOI: 10.3390/md21100514 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Marine Drugs, online erschienen am 28.09.2023. Verfasst von Yasuhiro Nishida und 10 weiteren Autor:innen. Beteiligte Einrichtung: Fuji Chemical Industries, Co., Ltd., 55 Yokohoonji, Kamiich-machi, Nakaniikawa-gun, Toyama 930-0405, Japan. Hauptthemen laut MEDLINE: Xanthophylls, Antioxidants. Die Arbeit wurde bisher 166-mal zitiert (Crossref) und nennt 929 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Astaxanthin (AX), a lipid-soluble pigment belonging to the xanthophyll carotenoids family, has recently garnered significant attention due to its unique physical properties, biochemical attributes, and physiological effects. Originally recognized primarily for its role in imparting the characteristic red-pink color to various organisms, AX is currently experiencing a surge in interest and research. The growing body of literature in this field predominantly focuses on AXs distinctive bioactivities and properties. However, the potential of algae-derived AX as a solution to various global environmental and societal challenges that threaten life on our planet has not received extensive attention. Furthermore, the historical context and the role of AX in nature, as well as its significance in diverse cultures and traditional health practices, have not been comprehensively explored in previous works. This review article embarks on a comprehensive journey through the history leading up to the present, offering insights into the discovery of AX, its chemical and physical attributes, distribution in organisms, and biosynthesis. Additionally, it delves into the intricate realm of health benefits, biofunctional characteristics, and the current market status of AX. By encompassing these multifaceted aspects, this review aims to provide readers with a more profound understanding and a robust foundation for future scientific endeavors directed at addressing societal needs for sustainable nutritional and medicinal solutions. An updated summary of AXs health benefits, its present market status, and potential future applications are also included for a well-rounded perspective.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Fuji Chemical Industries, Co., Ltd., 55 Yokohoonji, Kamiich-machi, Nakaniikawa-gun, Toyama 930-0405, Japan.
- AstaReal AB, Signum, Forumvägen 14, Level 16, 131 53 Nacka, Sweden.
- AstaReal, Inc., 3 Terri Lane, Unit 12, Burlington, NJ 08016, USA.
- First Department of Internal Medicine, Faculty of Medicine, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan.
- Graduate School of Science and Technology, Kwansei Gakuin University, 1 Gakuen-Uegahara, Sanda 669-1330, Japan.
- Research Institute for Bioresources and Biotechnology, Ishikawa Prefectural University, Suematsu, Nonoichi-shi 921-8836, Japan.
ORCID-Profile: Yasuhiro Nishida, Hideki Hashimoto, Norihiko Misawa
Zitieren
APA
Nishida, Y., Berg, P. C., Shakersain, B., Hecht, K., Takikawa, A., Tao, R., Kakuta, Y., Uragami, C., Hashimoto, H., Misawa, N., & Maoka, T. (2023). Astaxanthin: Past, Present, and Future. Marine Drugs, 21(10), 514. https://doi.org/10.3390/md21100514
Vancouver
Nishida Y, Berg PC, Shakersain B, Hecht K, Takikawa A, Tao R, et al. Astaxanthin: Past, Present, and Future. Marine Drugs. 2023;21(10):514. doi:10.3390/md21100514
BibTeX
@article{Nishida2023,
author = {Nishida, Yasuhiro and Berg, Pernilla Christina and Shakersain, Behnaz and Hecht, Karen and Takikawa, Akiko and Tao, Ruohan and Kakuta, Yumeka and Uragami, Chiasa and Hashimoto, Hideki and Misawa, Norihiko and Maoka, Takashi},
title = {Astaxanthin: Past, Present, and Future},
journal = {Marine Drugs},
year = {2023},
volume = {21},
number = {10},
pages = {514},
doi = {10.3390/md21100514}
}
EUVIMED